Join
Live feed
·
PRReleasevia Quantisnow
AstraZeneca PLC logo

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZN (AstraZeneca PLC) and more on Quantisnow.